FDA Cautious Stance on CAR-T Cell Therapies for Autoimmune Diseases
FDA is signaling a supportive but cautious regulatory posture toward the development of chimeric antigen receptor (CAR) T-cell therapies for autoimmune and rheumatic diseases, according to a perspective article published in the Annals of Internal Medicine by agency officials. CAR-T cell therapies — genetically engineered T cells programmed to target specific immune cell populations — have revolutionized treatment for certain blood cancers. Their success in hematological malignancies has prompted investigation into whether the same immunomodulatory approach can benefit patients with severe autoimmune and rheumatic conditions such as systemic lupus erythematosus and systemic sclerosis, where traditional immunosuppressive therapies often fail.
The FDA authors highlight the therapeutic promise of CAR-T strategies in autoimmune disease, particularly those targeting autoreactive B cells, a key driver in many rheumatic conditions. Early clinical reports suggest some patients can achieve deep and durable disease remission, potentially reducing or eliminating the need for long-term immunosuppression. This paradigm shift from chronic therapy to a one-time cellular reset is among the most compelling scientific rationales for pursuing CAR-T in this space. Unlike in oncology, where the goal is to persistently eradicate malignant cells, the autoimmune application seeks to reestablish immune tolerance by depleting pathogenic immune cells and enabling durable resetting of immune homeostasis.
The FDA regulators emphasize that because autoimmune and rheumatic diseases are highly heterogeneous — with variable severity, natural history, and patient populations — the agency intends to engage developers on a case-by-case basis. Tailored regulatory approaches will be needed to identify appropriate study designs, endpoints, and safety monitoring frameworks for trials in these conditions.
“The FDA acknowledges a distinction between severe versus mild-moderate autoimmune diseases and the types of diseases; for the former, the need to restrict the population to those with failure of two or more immunosuppressants is challenging because of the high risk for irreversible organ damage with recurrent relapses and limited available treatment options," the regulators write. "Therefore, the FDA will work with manufacturers on a case-by-case basis to encourage appropriate study populations in rheumatologic autoimmune disease.”
The agency’s stance reflects both interest in fostering innovation and concern about the unique safety challenges these therapies pose. CAR-T treatments can trigger adverse events such as cytokine release syndrome and neurotoxicity, and their long-term immunological consequences remain incompletely understood — risks that could be amplified in non-oncologic settings, the regulators say. This underscores the need for careful patient selection and thorough safety evaluation in clinical development programs.
“Given that many patients with autoimmune conditions are of reproductive age, the FDA will carefully consider the effect of therapy on fertility," they write. "To do this, the FDA has recommended that industry have long-term follow-up studies for CAR T-cell products in this setting, as is standard for genetic therapies and CAR T-cells for oncologic indications.”
While several early trials have reported encouraging outcomes, such as profound reduction in disease activity and sustained remission, larger controlled studies are still needed to define the risk-benefit profile of CAR-T in autoimmune diseases, FDA says.
The FDA’s perspective underscores its willingness to support scientifically rigorous advancement of these therapies, while maintaining a regulatory framework that balances access with patient safety.